Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7539972 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10930589 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL16124200 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL31399502 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1143253 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL25304378 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL28500270 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL8622940 | 1.00 | DUT (0.37) | DUTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL334934 | 0.98 | DUT (0.38) | DUTCYP4F2CYP4A11 | |
| SCHEMBL571057 | 0.91 | DUT (0.39) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2014797-A2 | Coating composition for interconnection part of electrode and plasma display panel including the same | Samsung SDI Co., Ltd. (KR) | 2009-01-14 | — | — | EP | claimed |
| US-20080303439-A1 | Coating composition for interconnection part of electrode and plasma display panel including the same | SAMSUNG SDI CO., LTD., A CORP. OF THE REPUBLIC OF KOREA (KR) | 2008-12-11 | — | — | US | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240417420-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-1159263-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000050391-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | MERCK & CO., INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| US-5290771-A | 19-nor-steroids | ROUSSEL UCLAF (FR) | 1994-03-01 | — | — | US | disclosed |
| US-5149696-A | Antiestrogens | ROUSSEL UCLAF (FR) | 1992-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | DUT 3010/4885LMNA 565/4885MEN1 4634/4885 |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | DUT 60/4885LMNA 269/4885MEN1 1950/4885 |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | DUT 1465/4885LMNA 1830/4885MEN1 3020/4885 |
| US-20240417420-A1 | POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC9, SIGLEC7, ASGR1 | DUT 594/4885LMNA 2540/4885MEN1 1737/4885 |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | DUT 60/4885LMNA 269/4885MEN1 1950/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | DUT 1499/4885LMNA 3613/4885MEN1 4557/4885 |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | DUT 60/4885LMNA 269/4885MEN1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.